Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional

Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia

ClinicalTrials.gov ID: NCT00035347

Public ClinicalTrials.gov record NCT00035347. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 1:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Multicenter, Open Label Trial Comparing Intravenous Zithromax® (Azithromycin) Plus Intravenous Rocephin® (Ceftriaxone) Followed By Oral Zithromax® (Azithromycin) With Intravenous Levaquin® (Levofloxacin) Followed By Oral Levaquin® (Levofloxacin) For The Treatment Of Moderate To Severely Ill Hospitalized Subjects With Community-Acquired Pneumonia

Study identification

NCT ID
NCT00035347
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Pfizer
Industry
Enrollment
219 participants

Conditions and interventions

Interventions

  • IV azithromycin Drug
  • ceftriaxone Drug
  • oral azithromycin Drug
  • IV levofloxacin Drug
  • oral levofloxacin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2000
Primary completion
Not listed
Completion
May 31, 2002
Last update posted
Mar 9, 2017

2001 – 2002

United States locations

U.S. sites
22
U.S. states
14
U.S. cities
21
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35233
Pfizer Investigational Site Long Beach California 90822
Pfizer Investigational Site Sylmar California 91342
Pfizer Investigational Site Sarasota Florida 34339
Pfizer Investigational Site Columbus Georgia 31902
Pfizer Investigational Site Columbus Georgia 31904
Pfizer Investigational Site Fort Eisenhower Georgia 30905
Pfizer Investigational Site Shawnee Mission Kansas 66204
Pfizer Investigational Site Louisville Kentucky 40206
Pfizer Investigational Site Detroit Michigan 48202
Pfizer Investigational Site Royal Oak Michigan 48073-6769
Pfizer Investigational Site Kirkwood Missouri 63122
Pfizer Investigational Site St Louis Missouri 63110
Pfizer Investigational Site Albuquerque New Mexico 87108-5154
Pfizer Investigational Site Mineola New York 11501
Pfizer Investigational Site New York New York 10003
Pfizer Investigational Site Winston-Salem North Carolina 27103
Pfizer Investigational Site Cleveland Ohio 44106
Pfizer Investigational Site Columbus Ohio 43202
Pfizer Investigational Site Philadelphia Pennsylvania 19140
Pfizer Investigational Site Sellersville Pennsylvania 18960
Pfizer Investigational Site San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00035347, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 9, 2017 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00035347 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →